La vendita allo scoperto per Weave Communications dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Weave Communications. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Weave Communications (NYSE:WEAV) Azioni, Report sulle vendite allo scoperto

Weave Communications

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, it enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue primarily from subscription services.

Weave Communications Inc

The collaboration supports the licensing of part of Curiosity Stream&#39;s content portfolio in China, Hong Kong, and Macau, bringing 56 unique titles, amounting to 148 hours of premium factual content, to audiences across these territories through various platforms. The deal encompasses a diverse range of programming, from short-form documentary series to premium long-form content.

News

CURI

Curiosity Inks Strategic Distribution Partnership With Off The Fence; Deal Broadens Company's Footprint Across China, Hong Kong, And Macau

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Needham analyst Kyle Peterson reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $350 price target.

Needham Reiterates Buy on Equifax, Maintains $350 Price Target

Needham analyst Mike Matson downgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Buy to Hold and maintains the price target from $86 to $86.

Downgrades

Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86

<a href="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/" title="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/">https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/</a>

Tech

AAPL

Reported Earlier, Apple's New iPhone Sales In China Rose 20% In First 3 Weeks

Weave Communications, Inc. 2024 Q2 - Results - Earnings Call Presentation

Weave Communications beats top-line and bottom-line estimates; initiates Q3 and raises FY24 outlook

Weave Communications, Inc. (WEAV) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Weave Communications (NYSE:<a href="https://investorplace.com/stock-quotes/weav-stock-quote/">WEAV</a>) just reported results for the second quarter of 2024.<ul><li>The company did not report any EPS for the quarter.</li><li>The company reported revenue of $50.59 million.</li><li>This was 3.94% better than the analyst estimate for revenue of $48.67 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/07/weav-stock-earnings-weave-communications-for-q2-of-2024/">WEAV Stock Earnings: Weave Communications Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

WEAV Stock Earnings: Weave Communications Beats Revenue for Q2 2024

Goldman Sachs analyst Kash Rangan reiterated a Hold rating on Weave Communications (WEAV – Research Report) yesterday and set a price target of $13...

Weave Communications: Hold Rating Despite Strong Q2 Performance and Positive Trends

There's a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Formfactor (FORM – Research Report), Tenable Holding...

Analysts Offer Insights on Technology Companies: Formfactor (FORM), Tenable Holdings (TENB) and Weave Communications (WEAV)

Stifel Nicolaus analyst J. Parker Lane maintained a Buy rating on Weave Communications (WEAV – Research Report) today and set a price target of $18...

Stifel Nicolaus Reaffirms Their Buy Rating on Weave Communications (WEAV)

The tech market is experiencing strong growth owing to government support and the rapid development of AI-related hardware and software. Amid this backdrop, investors could invest in fundamentally sound tech stocks Ricoh Company (RICOY), Weave Communications (WEAV), and AstroNova (ALOT), which are currently trading under $15. Continue reading... With the wide adoption of cutting-edge technologies like AI, integration of digital technologies, and increasing spending, the tech industry is on the front foot to contribute to worldwide growth and development. Also, its evolving application across all aspects of life broadens its possibilities.
Given the industry's bright outlook, it could be wise to invest in fundamentally strong tech stocks Ricoh Company, Ltd. (<a href="https://stocknews.com/stock/RICOY/">RICOY</a>), Weave Communications, Inc. (<a href="https://stocknews.com/stock/WEAV/">WEAV</a>), and AstroNova, Inc. (<a href="https://stocknews.com/stock/ALOT/">ALOT</a>), which are currently trading under $15.
The tech industry is growing at lightning speed, encompassing all aspects of our lives. In recent times, the technology market has made innumerable breakthroughs across diverse segments, including the healthcare, biotech, industrial, energy, software, and retail markets, with the rapid adoption of AI and other cutting-edge systems.
As per a research report by <a href="https://www.bain.com/about/media-center/press-releases/2024/market-for-ai-products-and-services-could-reach-up-to--$990-billion-by-2027-finds-bain--companys-5th-annual-global-technology-report/">Bain &amp; Company</a>, the market for AI-related hardware and software is projected to grow between 40% and 55% every year, totaling between $780 billion and $990 billion by 2027. Also, the government's attention towards powering American innovation is visible in <a href="https://www.whitehouse.gov/ostp/news-updates/2024/03/13/fact-sheet-president-bidens-2025-budget-invests-in-science-and-technology-to-power-american-innovation-expand-frontiers-of-whats-possible/">President Biden's 2025 Budget</a>, providing robust investments in AI R&amp;D.
These favorable trends have also accelerated investments and spending by tech companies in innovative technologies. <a href="https://www.gartner.com/en/newsroom/press-releases/2024-07-16-gartner-forecasts-worldwide-it-spending-to-grow-7-point-5-percent-in-2024">Gartner projects worldwide IT spending</a> to total $5.26 trillion in 2024, exhibiting a 7.5% growth from the previous year.
With this, the information technology market is expected to grow to $12.42 trillion in 2028, at a <a href="https://www.researchandmarkets.com/reports/5781249/information-technology-global-market-report">CAGR of 8.3%</a>, driven by globalized IT services, digital transformation, cybersecurity innovations, and changing e-commerce. Also, the revenue in the application development software market is anticipated to reach $250 billion by 2029, <a href="https://www.statista.com/outlook/tmo/software/application-development-software/worldwide">showing a 6.5% CAGR</a>.
Given these encouraging trends, let's delve deeper into the fundamentals of top tech stocks: RICOY, WEAV, and ALOT.
Ricoh Company, Ltd. (<a href="https://stocknews.com/stock/RICOY/">RICOY</a>)
Headquartered in Tokyo, Japan, RICOY provides office, commercial printing, and related solutions globally. The company operates in Digital services; Digital Products; Graphic Communications; Industrial Solutions; and Other segments.
In terms of forward EV/Sales, RICOY is trading at 0.48x, 83% lower than the industry average of 2.82x. Also, the stock's forward <a href="https://www.investopedia.com/terms/e/ev-ebitda.asp">EV/EBITDA</a> multiple of 7.28 is 49% lower than the industry average of 14.28. Also, its forward Price/Sales of 0.37x is 86.9% lower than the industry average of 2.83x.
On September 19, RICOY concluded a memorandum of understanding (MOU) with LG Electronics to collaborate on digital solutions for workplaces. The partnership will deliver elevated user experience and exceptional customer value for the B2B customers in the global market. Through the partnership, RICOY will further enhance its capability in the Workplace Experience domain.
RICOY's net sales increased 7.4% year-over-year to ¥574.38 billion ($3.99 billion) for the fiscal first quarter, which ended June 30, 2024, and its operating income was ¥6.33 billion ($43.95 million) for the period. Also, profit attributable to owners of the parent amounted to ¥7.80 billion ($54.12 million).
Street expects RICOY's revenue for the second quarter (ending September 2024) to increase 10.4% year-over-year to $4.22 billion. The company's revenue for the fiscal year (ending March 2025) is expected to grow 390.8% year-over-year to $17.22 billion. Furthermore, the company surpassed the consensus revenue estimates in three of the trailing four quarters.
Shares of RICOY have increased 11.8% over the past six months and 12% over the past year to close the last trading session at $10.27.
RICOY's robust growth prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Stability and Value. Within the <a href="https://stocknews.com/category/technology-hardware/">Technology - Hardware</a> industry, RICOY is ranked #11 out of 41 stocks.
<a href="https://stocknews.com/stock/RICOY/">Click here</a> to access additional ratings of RICOY for Quality, Growth, Sentiment, and Momentum.
Weave Communications, Inc. (<a href="https://stocknews.com/stock/WEAV/">WEAV</a>)
WEAV offers a customer experience and payments software platform. The company's platform allows small and medium-sized healthcare businesses to maximize the value of their patient interactions and minimize the time and effort spent on manual or mundane tasks.
On August 27, WEAV announced Payment Reminders, an enhancement feature designed to help improve revenue cycle management by allowing practices to continue to collect more outstanding balances with less effort by enabling practices to turn each Weave payment invoice or Text to Pay request into a "set-it-and-forget-it" collection system.
On July 30, WEAV integrated with eClinicalWorks, the largest cloud-based EHR software in the U.S. The integration delivers additional value to WEAV customers through streamlined operational efficiency, improved patient experience, and enhanced data accuracy.
WEAV's revenue rose 21.4% year-over-year to $50.59 million during the second quarter that ended June 30, 2024. Its non-GAAP gross profit grew 28.5% from the year-ago value to $36.37 million. The company's free cash flow amounted to $21.22 million, indicating growth of 2183.8% year-over-year.
Analysts expect WEAV's revenue for the third quarter (ending September 2024) to increase 18% year-over-year to $51.38 million. For the fiscal year 2024, the company's revenue is expected to grow 18.5% year-over-year to $201.95 million. Also, the company has topped the consensus EPS and revenue estimates in all of the trailing four quarters.
WEAV's shares have gained 9.8% over the past month and 49% over the past year to close the last trading session at $12.11.
WEAV's sound fundamentals are reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
The stock has a B grade for Quality, Growth, and Sentiment. Within the <a href="https://stocknews.com/category/software-application/">Software - Application</a> industry, WEAV is ranked #21 among the 129 stocks.
In addition to the POWR Ratings we've stated above, we also have WEAV ratings for Momentum, Value, and Stability. Get all WEAV ratings <a href="https://stocknews.com/stock/WEAV/">here</a>.
AstroNova, Inc. (<a href="https://stocknews.com/stock/ALOT/">ALOT</a>)
ALOT designs develops, manufactures, and distributes specialty printers and data acquisition and analysis systems internationally. The company operates in segments like Product Identification (PI) and Test &amp; Measurement (T&amp;M).
In terms of trailing-12-month non-GAAP P/E, ALOT is trading at 30.21x, 28.6% lower than the industry average of 23.49x. Also, the stock's trailing-12-month Price/Sales multiple of 0.64 is 77.6% lower than the industry average of 2.87. Also, its trailing-12-month Price/Cash Flow of 6.64x is 65.7% lower than the industry average of 19.35x.
On June 5, ALOT and the recently acquired MTEX NS subsidiary launched groundbreaking new innovative and sustainable printing technologies. The products launched included AQUAFLEX from MTEX NS, TrojanLabel T2-PRO system, ATOM 3 by MTEX NS, FLEXPACK series by MTEX NS, and MULTI 800 by MTEX NS.
The introduced solutions expanded the company's portfolio and reinstated its dedication to driving innovation and delivering value to customers across diverse market segments.
During the second quarter, which ended August 3, 2024, ALOT's revenue increased 14.1% year-over-year to $40.54 million, and its gross profit grew 47.5% from the year-ago value to $14.33 million. The company's non-GAAP net income came in at $572 thousand and $0.08 per common share for the quarter, respectively.
Furthermore, the company's total current assets stood at $83.06 million as of August 3, 2024, compared to $76.67 million as of January 31, 2024.
ALOT's stock has soared 5.6% over the past year to close the last trading session at $12.99.
ALOT's POWR Ratings reflect its robust outlook. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
ALOT has an A grade for Value. The stock also has a B grade for Growth and Sentiment. It is ranked #4 among the 41 stocks in the Technology - Hardware industry.
<a href="https://stocknews.com/stock/ALOT/">Click here</a> to access additional ALOT ratings for Stability, Quality, and Momentum.Top of Form
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>
&nbsp;

<hr />
RICOY shares were trading at $10.27 per share on Thursday afternoon, down $0.26 (-2.42%). Year-to-date, RICOY has gained 33.30%, versus a 21.54% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/ricoy-weav-alot-3-tech-stocks-under-15-you-dont-want-to-miss/>3 Tech Stocks Under $15 You Don't Want to Miss</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Comments

Weave Communications

Vendite allo scoperto

Weave Communications (NYSE:WEAV) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO